metricas
covid
Buscar en
Gastroenterología y Hepatología (English Edition)
Toda la web
Inicio Gastroenterología y Hepatología (English Edition) Evaluation of the clinical and economic value of sofosbuvir/velpatasvir (SOF/VEL...
Journal Information
Vol. 47. Issue 10.
(December 2024)
Share
Share
Download PDF
More article options
Visits
7
Vol. 47. Issue 10.
(December 2024)
Original article
Evaluation of the clinical and economic value of sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic hepatitis C in Spain during the last 5 years
Evaluación del valor clínico y económico de sofosbuvir/velpatasvir (SOF/VEL) en pacientes con hepatitis C crónica en España durante los últimos 5 años
Visits
7
Rafael Estebana, Raquel Domínguez-Hernándezb,
Corresponding author
rdominguez@porib.com

Corresponding author.
, Helena Canteroc, Miguel Ángel Casadob
a Hospital Vall’ d’Hebrón, Barcelona, Spain
b Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain
c Gilead Sciences, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (1)
Table 1. Sensibility analysis: number of cases with each treatment and their costs.
Abstract
Objective

Direct-acting antivirals for the treatment of hepatitis C virus (HCV) represented a paradigm shift. In 2017, sofosbuvir/velpatasvir (SOF/VEL-Epclusa®) was approved, which showed a high cure rate in all patient, contributing to HCV elimination. The analysis aimed to quantify the clinical and economic value of SOF/VEL in HCV chronic patients since its approval in Spain.

Methods

An economic evaluation was elaborated adapting a Markov model that simulated the lifetime disease progression in of all HCV chronic patients treated with SOF/VEL (30,488 patients) since its launch (5-years), compared to previous therapies. Patients entered the model and were distributed between the fibrosis states (F0-to-F4) in treated and untreated. All patients (100%) were treated with SOF/VEL regardless of their fibrosis, and 49% with previous therapies in ≥F2. The average sustained viral response (SVR) rates 98.9% SOF/VEL versus 61.0% previous therapies. All parameters for the analysis were obtained from real-life data and literature. Only direct healthcare costs associated with disease management were included. The SOF/VEL value was measured as the number of hepatic complications avoided and their associated cost, and hepatic mortality compared to previous therapies. National Health System perspective and a 3% discount rate was applied.

Results

SOF/VEL decreased the number of liver complications, avoiding 92% decompensated cirrhosis, 80% hepatocellular carcinomas, and 87% liver transplants, as well as 85% liver-related mortality. Their cost associated was reduced, amounting to savings of 197M€.

Conclusion

SOF/VEL adds relevant value to the HCV treatment, reducing the clinical and economic disease burden and contributing to HCV elimination in Spain.

Keywords:
DAAs
Health economics
Hepatitis C
Sofosbuvir/velpatasvir
Value
Resumen
Objetivo

Los antivirales de acción directa para el tratamiento del virus de la hepatitis C (VHC) representaron un cambio de paradigma. En 2017 se aprobó sofosbuvir/velpatasvir (SOF/VEL-Epclusa®), con elevadas tasas de curación en todos los pacientes, contribuyendo a la eliminación VHC. El objetivo fue evaluar el valor clínico y económico de SOF/VEL en pacientes crónicos desde su aprobación en España.

Métodos

Se adaptó un modelo de Markov que simulaba la progresión de la enfermedad durante toda la vida de pacientes crónicos tratados con SOF/VEL (30.488 pacientes) desde su lanzamiento (5 años), versus terapias previas. Los pacientes entraron al modelo distribuidos entre los estados de fibrosis (F0-F4) en tratados y no tratados. Todos los pacientes fueron tratados con SOF/VEL independientemente de su fibrosis, y el 49% con terapias previas (≥F2). La respuesta viral sostenida promedio: 98,9% SOF/VEL versus 61,0% terapias previas. Los parámetros para el análisis se obtuvieron de datos reales y literatura. Solo se incluyeron costes sanitarios directos asociados al manejo de la enfermedad. El valor SOF/VEL se midió como el número de complicaciones hepáticas evitadas y su coste, y la mortalidad hepática versus terapias previas. Se aplicó la perspectiva del Sistema Nacional de Salud y una tasa de descuento (3%).

Resultados

SOF/VEL disminuyó las complicaciones hepáticas, evitando el 92% cirrosis descompensadas, el 80% hepatocarcinomas y el 87% trasplantes hepáticos, así como el 85% la mortalidad hepática; generando ahorros de 197 millones de euros.

Conclusiones

SOF/VEL añade un valor relevante al tratamiento del VHC, reduciendo la carga clínica y económica de la enfermedad y contribuyendo a la eliminación VHC en España.

Palabras clave:
Antivirales de acción directa
Economía de la salud
Hepatitis C
Sofosbuvir/velpatasvir
Valor

Article

These are the options to access the full texts of the publication Gastroenterología y Hepatología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Gastroenterología y Hepatología (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos